Skip Navigation


Cardiovascular Research Advance Access first published online on April 27, 2009
This version [Corrected Proof] published online on May 22, 2009
Cardiovascular Research, doi:10.1093/cvr/cvp132
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
83/3/519    most recent
cvp132v2
cvp132v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hafstad, A. D.
Right arrow Articles by Aasum, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hafstad, A. D.
Right arrow Articles by Aasum, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

Cardiac peroxisome proliferator-activated receptor-{alpha} activation causes increased fatty acid oxidation, reducing efficiency and post-ischaemic functional loss

Anne D. Hafstad1,{dagger}, Ahmed M. Khalid1,{dagger}, Martin Hagve1, Trine Lund1, Terje S. Larsen1, David L. Severson2, Kieran Clarke3, Rolf K. Berge4 and Ellen Aasum1,*

1 Department of Medical Physiology, Institute of Medical Biology, Faculty of Medicine, University of Tromsø, N-9037 Tromsø, Norway
2 Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada T2 N 4N1
3 Department of Physiology, Anatomy and Genetics, University of Oxford, Parks Road, Oxford OX1 5DG, UK
4 The Lipid Research Group, Institute of Medicine, University of Bergen, Bergen, Norway

* Corresponding author. Tel: +47 77 64 64 86; fax: +47 77 64 54 40. E-mail address: ellen.aasum{at}uit.no

Aims: Myocardial fatty acid (FA) oxidation is regulated acutely by the FA supply and chronically at the transcriptional level owing to FA activation of peroxisome proliferator-activated receptor-{alpha} (PPAR{alpha}). However, in vivo administration of PPAR{alpha} ligands has not been shown to increase cardiac FA oxidation. In this study we have examined the cardiac response to in vivo administration of tetradecylthioacetic acid (TTA, 0.5% w/w added to the diet for 8 days), a PPAR agonist with primarily PPAR{alpha} activity.

Methods and results: Despite the fact that TTA treatment decreased plasma concentrations of lipids [FA and triacylglycerols (TG)], hearts from TTA-treated mice showed increased mRNA expression of PPAR{alpha} target genes. Cardiac substrate utilization, ventricular function, cardiac efficiency, and susceptibility to ischaemia-reperfusion were examined in isolated perfused hearts. In accordance with the mRNA changes, myocardial FA oxidation was increased 2.5-fold with a concomitant reduction in glucose oxidation. This increase in FA oxidation was abolished in PPAR{alpha}-null mice. Thus, it appears that the metabolic effects of TTA on the heart must be owing to a direct stimulatory effect on cardiac PPAR{alpha}. Hearts from TTA-treated mice also showed a marked reduction in cardiac efficiency (because of a two-fold increase in unloaded myocardial oxygen consumption) and decreased recovery of ventricular contractile function following low-flow ischaemia.

Conclusion: This study for the first time observed that in vivo administration of a synthetic PPAR{alpha} ligand elevated FA oxidation, an effect that was also associated with decreased cardiac efficiency and reduced post-ischaemic functional recovery.

KEYWORDS Cardiac metabolism; Glucose oxidation; Fatty acid oxidation; Ischaemia-reperfusion; Cardiac function; Cardiac efficiency; PPAR{alpha} target genes

Time for primary review: 21 days

{dagger} Both the authors have made equal contributions to this paper.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.